Microdosing LSD for Health & Longevity

Evidence Review created on 09/29/2026 using AI4L + evidence-mcp / Sonnet 5.5

Also known as: LSD Microdosing, Low-Dose LSD, Lysergic Acid Diethylamide Microdosing, LSD-25 Microdosing, Lysergide Microdosing

Motivation

Microdosing LSD (lysergic acid diethylamide) means taking repeated, very small amounts of a powerful hallucinogenic drug, roughly one-tenth of a typical dose, so that no hallucinations occur. People who follow the practice hope for a steadier mood, sharper focus and a more resilient brain as they age.

LSD was first made in 1938, and its effects were discovered in 1943. The modern form of microdosing spread in the early 2010s through personal accounts, and laboratory groups have since given small doses to healthy adults, older adults and patients, often comparing them with an inactive substance. Questions about the role of expectation, safety with repeated use and whether any effect lasts have drawn particular interest.

This review examines the evidence on microdosing LSD for health- and longevity-oriented adults: what controlled trials, reviews and early research report on possible benefits, risks, drug interactions, dosing schedules and monitoring, and how strong that evidence is, because many people already use the practice while controlled research has only recently begun.

Benefits - Risks - Protocol - Conclusion

Podcast, expert-commentary and review items (expert summaries rather than systematic searches) that give a high-level overview of microdosing LSD and the receptor pharmacology behind it.

Only three items qualified. No relevant content on LSD or psychedelic microdosing was found in substantial depth for Peter Attia (the site has psychedelic content, such as a 2021 article on psilocybin versus escitalopram that mentions microdosing schedules only briefly, but nothing on LSD microdosing), Chris Kresser (one interview with Ben Greenfield touches on LSD microdosing only in a brief passage within a broad biohacking discussion), Life Extension Magazine (its only microdosing article covers lithium) or Lifespan.io (its psychedelic articles cover psilocybin and lifespan in mice and psychedelics in Alzheimer’s disease, not microdosing).

Grokipedia

Psychedelic microdosing

Grokipedia’s closest entry covers LSD and psilocybin microdosing together: typical 5-20 µg LSD doses, the Fadiman protocol, and the gap between anecdotal reports and placebo-controlled findings.

Examine

LSD

Examine’s overview of LSD notes preliminary evidence for psychiatric use and links a research feed that includes a summary of psychedelic microdosing research.

ConsumerLab

No ConsumerLab article on LSD or microdosing exists; ConsumerLab tests commercially sold dietary supplements and does not cover controlled substances.

Systematic Reviews

Systematic reviews and meta-analyses (which statistically pool results across studies) of low-dose psychedelic research, all covering LSD together with psilocybin.

Mechanism of Action

LSD is an ergot-derived compound (from a grain fungus) acting mainly as a partial agonist (a drug that switches a receptor on, though not fully) at the serotonin 2A receptor (5-HT2A, a brain-cell docking site for serotonin). Its perceptual effects require this receptor: the 5-HT2A blocker ketanserin reverses them at full doses (Becker et al., 2023). Its pharmacology is otherwise complex, with binding to several other receptors (Passie et al., 2008), including 5-HT2B (linked to heart-valve scarring), and it dissociates very slowly from both 5-HT2A and 5-HT2B (Wacker et al., 2017).

Pharmacology: after sublingual (under-the-tongue) 10 µg, blood levels peak at about 1.5 hours, the drug reaches the brain, elimination half-life (time for the blood level to halve) is about 3 hours, and volume of distribution (how widely a drug spreads in the body) is about 33 litres (Morse et al., 2025). Perceptible effects begin near 10 µg; 5 µg produced none (Holze et al., 2021). The liver clears it, notably via CYP2D6 (an enzyme that clears many drugs); people with little or no CYP2D6 activity (poor metabolizers) had about 75% higher exposure (Vizeli et al., 2021).

Proposed health mechanisms include stimulant-like brain-activity changes and altered learning circuits (Hutten et al., 2024), plus anti-inflammatory 5-HT2A signaling in cell studies (Yu et al., 2008). A competing explanation attributes reported benefits to expectation: positive expectations predicted improvement (Kaertner et al., 2021), while reviewers argue expectation-only claims are premature (Polito & Liknaitzky, 2024, a review of 19 placebo-controlled studies).

Historical Context & Evolution

Albert Hofmann first synthesized LSD in 1938 at Sandoz while seeking a circulatory stimulant, and discovered its psychoactive effects in 1943. Through the 1950s and 1960s it served as an experimental agent in psychiatric research (temporarily inducing psychosis, a loss of contact with reality) and psychotherapy, generating nearly 10,000 papers and proving well tolerated in supervised settings, before becoming illegal in the mid-1960s (Passie et al., 2008). Hofmann reportedly suggested that low doses might replace Ritalin (methylphenidate, a prescription stimulant); James Fadiman later collected microdosing reports and popularized 10 µg every third day (Fadiman & Korb, 2019). Reports of better mood, energy and focus made the practice attractive.

Scientific opinion has shifted as controlled data arrived. Early accounts described improvement, but positive baseline expectations predicted gains (Kaertner et al., 2021), and a self-blinded study (participants concealed from themselves whether they took drug or placebo) of 191 participants found the placebo group improved equally (Szigeti et al., 2021). Laboratory trials mostly found small, transient effects (Murphy et al., 2024). Proponents counter that studies were small, tested few low doses in healthy volunteers and were susceptible to selection bias (participants not representative of the wider population), so a placebo-only explanation remains unproven (Polito & Liknaitzky, 2024); they also point to physiological effects, such as longer sleep the next night in a placebo-controlled trial, that expectation alone is unlikely to explain (Allen et al., 2024; the trial team included Mana Health, an industry partner). Both readings remain open.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the controlled human data show transient or inconsistent effects, and no clinical outcome or validated surrogate is replicated across trials.

Medium 🟩 🟩

Longer sleep on the night after dosing

In a six-week randomized trial of 80 healthy men, 10 µg LSD taken every third day was followed by longer sleep on the next night, with no loss of sleep on dosing days and no change in sleep-stage proportions. Sleep was tracked with a consumer wearable rather than polysomnography (overnight laboratory sleep recording). The mechanism is unknown, and the finding has not been replicated or tested in women or older adults.

Magnitude: +24.3 minutes of sleep on the night after dosing versus placebo (95% confidence interval, CI, 10.3-38.3 minutes; CI means the range likely to contain the true value), across 3,231 tracked nights (Allen et al., 2024).

Low 🟩

Mood and well-being ⚠️ Conflicted

Some trials report brief lifts in mood, energy and connectedness on dosing days, whereas others find no mood change and no advantage over placebo; observational gains track positive expectations. Lasting benefit has not been shown. Net reading: any effect is short-lived and hard to separate from expectation.

Magnitude: In an 80-person home-dosing trial, dose-day ratings of creativity, connectedness, energy, happiness and wellness rose (over 99% Bayesian posterior probability, a measure of how likely the effect is real) but no measure changed at six weeks (Murphy et al., 2023); four repeated doses in 56 adults did not improve mood or performance (de Wit et al., 2022); pooled randomized trials show depressive symptoms at SMD -0.19 (95% CI -0.56 to 0.19; SMD, standardized mean difference, is an effect size in standard-deviation units) (Meshkat et al., 2026); a 19-patient open-label (unblinded, no control group) depression trial reported a 59.5% fall in depression scores (Daldegan-Bueno et al., 2026); a self-blinded study found no group difference (Szigeti et al., 2021); expectation predicted gains (Kaertner et al., 2021).

Attention and cognitive performance ⚠️ Conflicted

Single low doses reduced attention lapses in one crossover study (each person receives every dose in turn), but a six-week trial in adults with attention-deficit/hyperactivity disorder found no benefit over placebo. Net reading: no reliable cognitive gain is established.

Magnitude: Attention lapses fell at 5 and 20 µg in 24 volunteers (Hutten et al., 2020); in 53 adults with attention-deficit/hyperactivity disorder, symptom scores improved by 7.1 points on 20 µg LSD twice weekly versus 8.9 points on placebo, with no group difference (Mueller et al., 2025); a pooled analysis of 14 studies found decreased cognitive control and no effect in other domains (Pinhas et al., 2026).

Pain tolerance ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

One crossover trial (24 volunteers) found longer cold-water pain tolerance after a single 20 µg dose; a later randomized trial of repeated 15 µg doses found none. This bears on experimental pain research rather than longevity. Net reading: no reliable pain-relieving effect is established.

Magnitude: 20 µg increased cold-water pain tolerance (p = 0.006, the chance of so large a difference arising randomly; partial eta-squared 0.09, the share of score variance explained by treatment) and lowered ratings of painfulness and unpleasantness; 5 µg had no significant effect (Ramaekers et al., 2021); four repeated 15 µg doses produced no pain-relieving effect on pain tolerance or pain ratings (Cavarra et al., 2025).

Speculative 🟨

Neuroplasticity marker (brain-derived neurotrophic factor) ⚠️ Conflicted

One study found blood levels of brain-derived neurotrophic factor (BDNF, a marker of neuroplasticity, the brain’s rewiring ability) rose after single doses; an 80-person microdosing trial found none. Net reading: unvalidated marker, no consistent change.

Anti-inflammatory and neuroprotective signaling

In cell studies, activating the serotonin 2A receptor with a related drug suppressed inflammation triggered by tumor necrosis factor-α (TNF-α, an inflammatory signal). No human study has measured inflammation or nerve-cell loss after LSD microdosing.

Lifespan extension in model organisms

A preprint (a study not yet peer reviewed) reported that LSD lengthened lifespan of the roundworm Caenorhabditis elegans with calorie-restriction-like changes. No mammal or human lifespan data exist.

Benefit-Modifying Factors

  • Genetics (CYP2D6): No study links genotype to benefit. People lacking CYP2D6 had about 75% higher LSD exposure and longer effects, which could change whether a given dose is perceptible (Vizeli et al., 2021).
  • Baseline biomarkers: Stimulant-like brain effects were strongest in people with low baseline arousal and attention, while memory-related effects were blunted in high memory performers, so baseline state shapes response (Hutten et al., 2024).
  • Sex: The largest home-dosing trial enrolled only men (Murphy et al., 2023), and reviews note gender bias, so sex-specific benefit is unknown (Ona & Bouso, 2020).
  • Pre-existing conditions: Volunteers with depressed mood reported stronger acute positive effects after 26 µg (Molla et al., 2024); adults with attention-deficit/hyperactivity disorder showed no benefit over placebo (Mueller et al., 2025).
  • Age: Older adults (mean age 62.9) tolerated 5-20 µg every fourth day for 21 days; efficacy was not the aim, so benefit is untested (Family et al., 2020). Eleusis, a company developing LSD-based Alzheimer’s treatments, ran the trial.
  • Expectation: Positive baseline expectations predicted greater well-being gains, so belief in the practice modifies reported benefit (Kaertner et al., 2021).

Potential Risks & Side Effects

High 🟥 🟥 🟥

Anxiety and unpleasant subjective effects

Treatment-related anxiety was the most notable adverse event in the largest home-dosing trial. Acute anxiety ratings also rose after single 5 and 20 µg doses in a dose-finding study and slightly in a pain study. Community surveys list increased anxiety among challenges. The effect is short-lived, but it prompted some participants to withdraw from trials.

Magnitude: 4 of 40 participants in the LSD group withdrew because of treatment-related anxiety (Murphy et al., 2023); 1 of 19 patients withdrew for anxiety in an open-label depression trial (Daldegan-Bueno et al., 2026); anxiety appeared in 6.7% of coded reports from 278 microdosers (Anderson et al., 2019); confusion and anxiety rose at 20 µg and anxiety at 5 µg in 24 volunteers (Hutten et al., 2020).

Reduced cognitive control

A preregistered (analysis plan filed in advance) meta-analysis of 14 studies (1,614 participants) found a significant decrease in cognitive control (goal-directed regulation of attention and behavior) and no detectable effect in other cognitive domains, whether testing occurred on or off the drug. Dose, substance and duration did not change the effect, which is small.

Magnitude: Pooled effect d = -0.34 (95% CI -0.62 to -0.06; d is a standardized effect size, 0.2 small and 0.5 medium) in the meta-analysis of Pinhas et al., 2026, as summarized by an umbrella review (a review of reviews) (Özaydın & Canlan Özaydın, 2026).

Blood pressure increases

Blood pressure rose modestly, within the normal range, after single 10-26 µg doses in two placebo-controlled laboratory trials, and a systematic review lists increased blood pressure among the most common microdosing adverse effects. Heart-rate changes were small or absent. The size is small, but effects of months of repeated dosing are unmeasured.

Magnitude: 10 µg raised diastolic (lower reading, p < 0.001) and 20 µg raised systolic (upper reading, p < 0.001) and diastolic (p = 0.013) blood pressure, by under 10 mmHg versus placebo and within the normal range (Ramaekers et al., 2021); 13 and 26 µg raised systolic pressure to peaks of 111.5 and 115.3 mmHg versus 105.4 on placebo (Bershad et al., 2019); heart rate rose by under 15% from baseline after 10 µg sublingual LSD (Morse et al., 2025) and was unchanged in both laboratory trials.

Medium 🟥 🟥

Physiological discomfort (self-reported)

Physiological discomfort was the most frequent challenge in a community study of 278 microdosers’ written reports, and a systematic review of 31 studies judged side effects typically dose-dependent, mild and short-lived. Drug-reference listings of full-dose LSD effects (Drugs.com) name nausea, loss of appetite, dry mouth, tremor and difficulty sleeping. Specific microdose symptoms are inconsistently reported, and most data are self-reported.

Magnitude: Physiological discomfort appeared in 18.0% of coded reports from 278 microdosers (Anderson et al., 2019); the review gives no pooled rate because side effects were assessed heterogeneously (Modzelewski et al., 2025).

Low 🟥

Psychiatric destabilization in predisposed individuals

Trials exclude people with psychotic (loss of contact with reality) or bipolar (with manic episodes of abnormally elevated mood and energy) disorders, so risk in predisposed individuals is untested under controlled conditions. Only isolated clinical cases and self-reports exist.

Magnitude: Not quantified in available studies. Trials exclude psychotic and bipolar disorders, leaving only isolated case reports and self-reports (Modzelewski et al., 2025).

Contaminated or misidentified product

Blotter papers (paper squares soaked in LSD) sold as LSD increasingly contain other substances; NBOMe compounds (potent look-alike hallucinogens with reported fatalities) are among them. The evidence is forensic seizure data from one region, not microdosing users.

Magnitude: In seized blotters from Santa Catarina, Brazil, the share containing LSD fell from 100% (2011) to 0.1% (2014) and 17.6% (2017) (de Souza Boff et al., 2020); NBOMe intoxications include fatalities (Zawilska et al., 2020).

Heart-valve disease from long-term 5-HT2B activation

Related drugs that chronically activate the 5-HT2B receptor (fenfluramine, pergolide) caused heart-valve disease (a narrative review, an expert summary rather than a systematic search), and LSD binds it. Eight weeks of dosing changed no valves in 19 patients; long-term risk is unmeasured.

Magnitude: 0 of 19 patients showed valve changes on echocardiography after eight weeks of dosing (Daldegan-Bueno et al., 2026); longer-term rates are not reported.

Hallucinogen persisting perception disorder

Persistent visual disturbances (hallucinogen persisting perception disorder; a narrative review) are uncommon and were described mainly after illicit full-dose LSD use. Risk at sub-perceptual doses is unknown.

Magnitude: Not quantified in available studies. Reports come from full-dose users, and no study has measured this outcome at sub-perceptual doses.

Speculative 🟨

Risk-Modifying Factors

  • Genetics (CYP2D6): Two of the four participants who withdrew for anxiety in an 80-person trial had intermediate-to-weak CYP2D6 activity, and poor metabolizers have about 75% higher LSD exposure (Morse et al., 2025; Vizeli et al., 2021).
  • Baseline biomarkers: Blood pressure rose at 10-20 µg (Ramaekers et al., 2021), and one trial excluded resting pressure above 140/90 mmHg (NCT07061886), making baseline pressure relevant.
  • Sex: Key safety data come from men (Murphy et al., 2023), so sex differences in adverse events are unknown (Ona & Bouso, 2020); pregnancy and breastfeeding are trial exclusions without safety data.
  • Pre-existing conditions: Trials exclude personal or first-degree family history of psychosis, seizure disorder, stroke and cardiovascular illness (NCT05177419), and bipolar disorder or past manic episodes (NCT04421105), leaving risk in these groups uncharacterized.
  • Age: Older volunteers had adverse-event rates no higher than placebo over 21 days (Family et al., 2020); age-related high blood pressure and valve disease make the unstudied long-term cardiac question more relevant.

Key Interactions & Contraindications

Prescription medications

  • Lithium (a mood-stabilizing drug): Absolute contraindication. In 62 online reports, 47% of lithium-plus-psychedelic experiences involved seizures (Nayak et al., 2021). Mitigation: avoidance of the combination.
  • Serotonergic antidepressants (drugs acting on serotonin, such as fluoxetine, paroxetine, sertraline, trazodone): Caution. After 3+ weeks of use, 28 of 32 users reported reduced or absent LSD effects (Bonson et al., 1996); the risk is dose escalation to compensate. Mitigation: keeping the dose fixed.
  • Tricyclic antidepressants (older mood-lifting drugs, such as amitriptyline, imipramine): Caution. An earlier report described increased LSD responses during chronic use (Bonson et al., 1996); older-adult trials excluded them (NCT04421105). Mitigation: avoidance during chronic use.
  • 5-HT2A blockers (drugs occupying the same receptor, such as ketanserin, risperidone, olanzapine): Monitor. Ketanserin shortened full-dose LSD effects from 8.5 to 3.5 hours (Becker et al., 2023); the others are expected to blunt effects similarly. Mitigation: avoidance on dosing days.
  • CYP2D6 inhibitors (drugs that slow this enzyme, such as bupropion, quinidine, terbinafine, paroxetine): Caution. Higher LSD exposure is predicted by analogy to poor metabolizers (about 75% more) (Vizeli et al., 2021); no direct study exists. Mitigation: dose reduction.
  • Ergot-derived drugs (methysergide, pergolide): Caution. Shared 5-HT2B activity could add to heart-valve scarring risk (Rouaud et al., 2024). Mitigation: avoidance, or cardiac imaging if unavoidable.
  • Stimulants (alertness-raising drugs, such as amphetamine, methylphenidate): Monitor. Additive rises in blood pressure and heart rate are expected; MDMA (ecstasy) with full-dose LSD raised both more than LSD alone (Straumann et al., 2023). Mitigation: blood-pressure checks and no stimulants on dosing days.

Over-the-counter medications

  • Decongestants (nasal-congestion relievers such as pseudoephedrine, phenylephrine) and dextromethorphan (a cough suppressant): Monitor. Additive blood-pressure or serotonin-related effects are theoretical; no studies exist. Mitigation: avoidance on dosing days.

Supplements

  • Serotonin-boosting supplements (St. John’s wort, 5-hydroxytryptophan, L-tryptophan): Caution. A blunted or unpredictable LSD response and added serotonergic effects are possible but untested; older-adult trials excluded these supplements (NCT04421105). Mitigation: avoidance on dosing days.
  • Stimulant supplements with additive effects (caffeine, yohimbine, synephrine): Monitor. They may add to blood-pressure, heart-rate and anxiety effects; no studies exist. Mitigation: limited intake on dosing days.
  • Mushroom-and-niacin “stacks” (combined regimens with lion’s mane and niacin): Caution. Common among microdosers, but no safety data exist, so effects on tolerability and cardiovascular load are unknown (Rootman et al., 2021). Mitigation: avoidance of stacking.

Other interventions

  • Full-dose psychedelics (LSD, psilocybin) and MDMA: Caution. MDMA prolonged full-dose LSD action and raised blood pressure and heart rate (Straumann et al., 2023). Mitigation: separation from microdosing days.
  • Alcohol and cannabis: Monitor. Interaction with microdoses is uncontrolled; both can worsen anxiety, the leading adverse event. Mitigation: avoidance on dosing days.

Populations who should avoid Microdosing LSD:

  • Personal or first-degree family history of a psychotic disorder (trial exclusion) (NCT07189299)
  • Bipolar disorder or any past manic episode (NCT04421105); anyone taking lithium
  • Resting blood pressure above 140/90 mmHg (NCT07061886)
  • History of seizure disorder, stroke or cardiovascular illness (NCT05177419)
  • Known heart-valve disease (long-term 5-HT2B valve safety is unmeasured)
  • Pregnancy, breastfeeding or planned pregnancy
  • Substance use disorder within the past 12 months
  • Suicidal ideation or behavior within the past 6-12 months
  • Age under 18 (no data)

Risk Mitigation Strategies

  • Screening for psychosis and mania risk: trials exclude personal and first-degree family history of psychosis and bipolar disorder before any dosing (NCT07189299; NCT04421105), which addresses psychiatric destabilization.
  • Low starting dose with slow titration: 5-8 µg starts, raised stepwise (titration) toward the 10 µg perception threshold (Holze et al., 2021), limit anxiety and unpleasant subjective effects.
  • Dose intervals of 3-4 days: every-third-day schedules keep receptor exposure intermittent, which addresses the unmeasured 5-HT2B heart-valve question.
  • Blood pressure and heart-rate checks: trials measured both before dosing and excluded resting pressure above 140/90 mmHg (NCT07061886), which addresses pressure increases.
  • Cardiac imaging for extended use: an echocardiogram (heart-valve ultrasound) at baseline and after several months, as an 8-week patient trial did (Daldegan-Bueno et al., 2026), addresses valve changes.
  • Driving and task restrictions on dosing days: trials restricted driving and machinery use after dosing (up to 48 hours in NCT05177419), which addresses accidents and errors from reduced cognitive control and anxiety at 5-20 µg.
  • Excluding interacting medications: older-adult trials excluded chronic lithium, tricyclic and serotonergic antidepressants, and serotonin-boosting supplements (NCT04421105), which addresses seizure risk and blunted or amplified responses.
  • Product verification (reagent test plus laboratory quantification): reagent tests screen identity and laboratory quantification measures content, which addresses NBOMe substitution and wrong strength (de Souza Boff et al., 2020).
  • Dose pause on emerging anxiety: treatment-related anxiety led four participants to withdraw from a home-dosing trial (Murphy et al., 2023); stopping dosing ends exposure, which addresses anxiety escalation.
  • Sub-perceptual dose range: perceptible effects begin near 10 µg (Holze et al., 2021); remaining below full doses addresses hallucinogen persisting perception disorder, described mainly after illicit full-dose use.

Therapeutic Protocol

  • Standard community protocol (James Fadiman): 10 µg every third day (one dosing day, two rest days), reported in surveys lasting one week to four months (Fadiman & Korb, 2019).
  • Home-dosing trial (University of Auckland): 10 µg every third day for six weeks, 14 doses, first supervised and the rest self-administered (Murphy et al., 2023).
  • Depression trial (University of Auckland): 8 µg first dose, then 6-20 µg sublingually twice weekly for eight weeks with titration (Daldegan-Bueno et al., 2026).
  • Attention trial (University Hospital Basel and Maastricht University): 20 µg twice weekly for six weeks, 12 doses (Mueller et al., 2025).
  • Older-adult regimen (Eleusis): 5, 10 or 20 µg every fourth day for 21 days, six doses (Family et al., 2020).
  • Repeated-dose laboratory regimen (University of Chicago): four sessions of 13 or 26 µg at 3-4-day intervals (de Wit et al., 2022).
  • Time of day: No trial compared dosing times. Effects begin about 1.1 hours after 10 µg, peak near 2.5 hours and end near 5 hours (Holze et al., 2021); earlier dosing would avoid overlap with sleep, an unstudied inference.
  • Half-life: Plasma half-life is about 2.7-3 hours (Holze et al., 2021; Morse et al., 2025).
  • Single versus split doses: Every protocol above uses one dose per dosing day; splitting is unstudied.
  • Genetics: CYP2D6 poor metabolizers have longer half-lives and about 75% higher exposure, which may shift the effective dose (Vizeli et al., 2021).
  • Sex: The largest home-dosing trial enrolled men only (Murphy et al., 2023); a randomized trial in women with premenstrual disorders is planned (NCT07189299).
  • Age: Older-adult dosing (ages 55-75) used every-fourth-day spacing and showed no impairment of cognition, balance or proprioception (sense of body position) (Family et al., 2020).
  • Baseline biomarkers: Response depends on baseline arousal and attention (Hutten et al., 2024), and trials screen resting blood pressure before dosing.
  • Pre-existing conditions: People with depressed mood reported stronger acute effects at 26 µg (Molla et al., 2024); trials exclude psychosis and mania.

Discontinuation & Cycling

  • Duration: Controlled trials lasted three to eight weeks; no data address lifelong use, and long-term cardiac effects are unmeasured (Rouaud et al., 2024).
  • Withdrawal effects: None were reported in the trial publications reviewed, and classic psychedelics are not considered to cause dependence (Nichols, 2016).
  • Tapering: Trials stopped dosing without a taper; mood gains in an open-label depression trial were sustained for up to six months after stopping (Daldegan-Bueno et al., 2026).
  • Cycling: Community protocols alternate weeks of dosing with rest weeks; an eight-week twice-weekly patient trial found no tolerance or sensitization (an increasing response with repeated dosing) (Daldegan-Bueno et al., 2026), so cycling for efficacy is unproven.
  • Reassessment points: Stopping after a defined cycle allows comparison of dosing and non-dosing periods, helping separate drug effect from expectation (Szigeti et al., 2021).

Sourcing and Quality

  • Legal supply: No consumer-grade LSD is legally available; pharmaceutical-grade material exists only for research, such as the sublingual formulation MB-22001 used in the Auckland depression trials (Donegan et al., 2023).
  • Formulation: Trials used pharmaceutical-grade LSD base or tartrate with verified dose (Holze et al., 2021; de Wit et al., 2022), unlike blotter papers, whose per-square content varies.
  • Substitution: Seized blotters increasingly contained other compounds, including NBOMe and fentanyl, instead of LSD (de Souza Boff et al., 2020).
  • What to look for: Reagent tests (for example Ehrlich reagent, which reacts with indole compounds such as LSD) screen for identity but not dose; laboratory quantification is the only reliable measure of content.
  • Brands and pharmacies: No reputable retail brands or compounding pharmacies exist in most jurisdictions; regulated research supply includes Auckland’s Mana Health, an industry partner in the Auckland trials.
  • Storage: LSD degrades with light, heat and chlorinated water, so dilution errors and storage conditions affect delivered dose.

Practical Considerations

  • Time to effect: Acute effects begin about 1.1 hours after 10 µg (Holze et al., 2021); no lasting benefit was shown after six weeks (Murphy et al., 2023).
  • Common pitfalls: Likely pitfalls include dosing by cutting blotters (uneven content), exceeding the perceptual threshold, stacking stimulants, expecting benefit without blinding (concealing who receives the drug), and skipping family-history screening.
  • Regulatory status: LSD is a Schedule I controlled substance (a US category for drugs with no accepted medical use) and not an approved medicine; single perceptible doses of 50-100 µg LSD are in phase 3 trials for anxiety (NCT06809595).
  • Cost and accessibility: Legal access is limited to clinical trials, so most microdosers rely on illicit supply, which brings legal and product-identity risks.

Interaction with Foundational Habits

  • Sleep: Direct. In 80 men, sleep lengthened by 24.3 minutes the night after a 10 µg dose with no loss on dosing days (Allen et al., 2024); stimulant-like arousal effects make early-day timing a reasoned but unstudied choice.
  • Nutrition: None established. No food-effect or diet-interaction data exist for microdoses; interactions with serotonergic supplements and stimulants are covered under interactions.
  • Exercise: Indirect. Survey respondents attributed more walking and exercise to microdosing, without a control group (Rhonda Patrick’s digest); blood pressure rose at 10-20 µg, so hard training near the 2.5-hour peak is an unstudied combination.
  • Stress management: Indirect and possibly potentiating. Survey respondents reported more contemplative practice and stress management (Rhonda Patrick’s digest), but positive expectations predicted well-being gains (Kaertner et al., 2021), and anxiety was the leading adverse event.

Monitoring Protocol & Defining Success

Baseline testing establishes resting blood pressure and heart rate, a heart-valve ultrasound, a rhythm tracing, liver enzymes and validated mood and anxiety questionnaire scores, plus psychiatric-history and medication review, mirroring trial screening and giving later changes a clear, personal reference point. Ongoing monitoring repeats blood pressure, heart rate, mood scores and sleep at 1, 4 and 8 weeks, then every 3 months while dosing continues; the ultrasound and liver enzymes are repeated after 6-12 months of use and yearly thereafter. Each check compares with the person’s own baseline, recording dosing and non-dosing days separately, with dose-day readings taken near the 2.5-hour peak.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pressure (seated, resting) Below 120/80 mmHg Rose at 10-20 µg (Ramaekers et al., 2021); one trial excluded readings above 140/90 mmHg (NCT07061886) Conventional normal is below 130/80 (elevated from 120-129); readings are typically two in the morning, plus one about 2.5 hours after a dose
Resting heart rate 50-70 beats per minute Rose under 15% at 10 µg (Morse et al., 2025); marks stimulant load Conventional range is 60-100; measured after 5 minutes of rest
Echocardiogram (heart-valve ultrasound) No new or worsening valve regurgitation (backward blood leak) versus baseline Related drugs caused valve scarring through 5-HT2B (Rouaud et al., 2024) Baseline, then after 6-12 months of continued dosing; trace regurgitation is common and normal
Electrocardiogram No established LSD-specific target; track corrected QT interval and rhythm change from baseline Used as safety measure in a patient trial (Daldegan-Bueno et al., 2026) Older-adult trial excluded a corrected QT interval (heart-rhythm timing measure) above 450 milliseconds (NCT04421105)
Liver enzymes (ALT, AST) ALT at or below 25 U/L LSD is cleared by liver enzymes; a patient trial tracked blood safety labs (Daldegan-Bueno et al., 2026) ALT = alanine aminotransferase, AST = aspartate aminotransferase; conventional ALT limit is about 40 U/L
CYP2D6 genotype (one-time) No optimal target; note metabolizer status (poor, intermediate, normal, ultrarapid) Poor metabolizers had about 75% higher exposure (Vizeli et al., 2021) Not routine; most relevant with CYP2D6-inhibiting drugs
Mood and anxiety questionnaire scores No established target; track change from own baseline (lower is better) Anxiety is the leading adverse event (Murphy et al., 2023); tests claimed benefit Examples: PHQ-9 (Patient Health Questionnaire-9, 9-item depression scale), GAD-7 (7-item anxiety scale); same time of day
Sleep duration (wearable) 7-9 hours per night; track change from baseline The one controlled sleep signal was +24 minutes (Allen et al., 2024) Wearable estimates are approximate; nights after dosing are compared with other nights

Qualitative markers:

  • Sleep quality and morning refreshment
  • Daytime energy and mood stability
  • Anxiety or restlessness after dosing
  • Focus and cognitive clarity
  • Any perceptual effects (a sign the dose is too high)

Emerging Research

  • Premenstrual disorders (Basel): NCT07189299 will randomize 150 women to 10 µg LSD daily, every other day or placebo during the late luteal phase (the days before menstruation) over three cycles; the primary endpoint (the main outcome measured) is symptom burden. Not yet recruiting.
  • Expectancy and blinding (Chicago): NCT07061886 tests 13 µg LSD versus placebo in 42 healthy adults told either the exact drug or an uncertain identity, separating drug effect from expectation. Completed June 2026; no results posted.
  • Neuroplasticity (Fribourg): NCT05177419 is a crossover trial of 100 µg versus low-dose LSD in 45 healthy adults measuring motor-cortex plasticity and blood BDNF. Completed March 2025; no results posted.
  • Depression (Auckland): Open-label results showed a 59.5% fall in depression scores and no valve changes in 19 patients (Daldegan-Bueno et al., 2026); a randomized active-placebo follow-up (a comparison substance with noticeable effects, which hides who received LSD) is described in Daldegan-Bueno et al., 2024 (registered outside ClinicalTrials.gov; no NCT ID).
  • Older adults and neurodegeneration (nerve-cell loss): NCT04421105 tested 5-20 µg LSD in 48 volunteers aged 55-75 (Family et al., 2020); no efficacy trial for cognitive decline was found in the literature searched.
  • Long-term cardiac safety: A mouse preprint found no cardiac change after LSD microdosing (Effinger et al., 2025); human evidence beyond eight weeks could strengthen or weaken the case.
  • Aging biology: The Caenorhabditis elegans lifespan finding (Carrilho et al., 2025) awaits mammalian tests that could support or refute lifespan effects.
  • Perceptible-dose LSD phase 3 program (not microdosing): NCT06809595 (anxiety, 245 participants) and NCT06941844 (depression, 149) will enlarge the human safety database.

Conclusion

Microdosing LSD means repeated doses of a powerful hallucinogenic drug small enough to avoid perceptible effects. For health- and longevity-oriented adults, the controlled human evidence points to short-lived effects rather than lasting gains, and no benefit reaches the highest evidence level. The best-supported findings concern side effects: anxiety, some physical discomfort, small blood pressure rises and a small reduction in the ability to regulate attention and behavior. Longer sleep the night after a dose rests on a single trial. Brief lifts in mood and energy on dosing days appear in some studies but not others, while reports of sharper focus, pain tolerance, reduced inflammation and longer lifespan rest on limited, indirect, animal or cell evidence.

Whether apparent benefits reflect the drug or positive expectation remains open, as do the effects of years of repeated use on the heart and brain. Effects on brain aging are unknown, since older adults have been examined only for short-term safety and side effects. Most trials were short and small, enrolled healthy volunteers and often only men, and some involved investigators affiliated with companies developing LSD-based products (Eleusis, Mana Health). Product quality, legal status and interactions with common medications add practical uncertainty.

Top - Benefits - Risks - Protocol